Best-Selling Immunology Drugs in Q3 2025: Revenue Leaders and Market Dynamics

Q3 2025 reinforced immunology’s position as a core growth engine for large pharmaceutical companies. Several franchises now generate quarterly revenues well above $1 billion, reflecting sustained demand across dermatology, respiratory, gastroenterology, and rheumatology indications.

At the top of the category, Sanofi and Regeneron’s Dupixent continues to widen the gap with competitors, while AbbVie’s Skyrizi and Rinvoq combination has effectively replaced Humira as the company’s immunology backbone. Meanwhile, legacy biologics are adapting through pricing, access, and targeted differentiation strategies.

Top-Selling Immunology Drugs in Q3 2025

Quarterly sales reflect company-reported Q3 2025 revenues. Sanofi and Takeda figures were converted to USD using the average Q3 2025 exchange rate.

Franchise-Level Dynamics

Dupixent Sets a New Immunology Benchmark

Dupixent delivered $4.8 billion in Q3, reinforcing its position as the world’s best-selling immunology drug. Sanofi and Regeneron continue to execute a disciplined label-expansion strategy across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.

In June 2025, the U.S. FDA approved Dupixent as the first targeted therapy for adults with bullous pemphigoid, extending the franchise into a new dermatologic indication and supporting continued revenue durability.

AbbVie’s Post-Humira Transition Is Largely Complete

AbbVie’s immunology reset remains one of the most closely watched commercial shifts in pharma. Skyrizi generated $4.71 billion in Q3, supported by ongoing share gains in psoriasis and inflammatory bowel disease, including ulcerative colitis.

Rinvoq added $2.18 billion, reflecting strong uptake across rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, and ulcerative colitis. Together, these assets now fully offset Humira’s U.S. loss of exclusivity and represent a structurally higher-margin portfolio.

Cosentyx and the Evolution of Mature Biologics

Cosentyx generated $1.70 billion, sustaining Novartis’ leadership in IL-17-driven diseases such as psoriasis and axial spondyloarthritis. In 2025, Novartis introduced a U.S. direct-to-patient pricing option at roughly 55 percent below list, illustrating how established biologics are adapting to access pressure without exiting core indications.

Entyvio’s Differentiation in a Crowded IBD Market

Entyvio delivered $1.67 billion, underscoring the continued relevance of gut-selective immunology in inflammatory bowel disease. Despite increasing competition from IL-23 biologics and oral small molecules, Entyvio maintains a differentiated position due to its mechanism and long-term safety profile.

Johnson & Johnson’s IBD Succession Plan

Stelara generated $1.57 billion in Q3 but faces U.S. loss of exclusivity in 2025. Johnson & Johnson is clearly positioning Tremfya as its successor. Tremfya reached $1.42 billion this quarter, supported by Phase III GALAXI data in Crohn’s disease showing higher rates of endoscopic response and remission versus Stelara.

Conclusion

Q3 2025 confirms that immunology has entered a new commercial phase. No longer defined by a single dominant product, the category is now shaped by multiple large franchises, each supported by indication expansion, lifecycle management, and increasingly sophisticated access strategies. As newer biologics rival the scale Humira once achieved, immunology remains one of the most strategically important and competitive segments in global pharma.